In the claims:

- 1. (Currently Amended) A flowable pharmaceutical composition consisting essentially of eomprising: a biocompatible oil and a therapeutically effective amount of a pharmaceutically acceptable inorganic salt of a caine analgesic agent, wherein said salt of said caine analgesic agent is at most sparingly soluble in said pharmaceutical composition, wherein said salt of said caine analgesic agent comprises at least about 3% and no more than about 80% by weight of said flowable pharmaceutical composition, and wherein said flowable pharmaceutical composition is suitable for administration to a patient by injection.
- 2. (Original) The flowable pharmaceutical composition of claim 1, wherein said biocompatible oil is a vegetable oil.
- 3. (Original) The flowable pharmaceutical composition of claim 2, wherein said biocompatible oil is one of the following: canola oil, castor oil, coconut oil, corn oil, cottonseed oil, olive oil, palm oil, peanut oil, rapeseed oil, soy bean oil, safflower oil, sesame oil, soybean oil, sunflower oil, and mixtures thereof.
- 4. (Original) The flowable pharmaceutical composition of claim 1, wherein said biocompatible oil is sesame oil.
- 5. (Original) The flowable pharmaceutical composition of claim 1, wherein said biocompatible oil has a viscosity below about 140 cSt at 20 °C.
- 6. (Original) The flowable pharmaceutical composition of claim 1, wherein said pharmaceutical composition has a viscosity below about 90 cSt at 20 °C.
- 7. (Original) The flowable pharmaceutical composition of claim 1, wherein said biocompatible oil has a viscosity above about 45 cSt at 20 °C.
- 8. (Original) The flowable pharmaceutical composition of claim 1, wherein said pharmaceutical composition has a viscosity between about 60 and 90 cSt at 20 °C.
- 9. (Original) The flowable pharmaceutical composition of claim 1, wherein said pharmaceutical composition is flowable at room temperature.
- 10. (Original) The flowable pharmaceutical composition of claim 1, wherein said biocompatible oil has a dielectric constant below about 20.

B3176942.1 - 2 -

- 11. (Original) The flowable pharmaceutical composition of claim 1, wherein said pharmaceutical composition has a dielectric constant below about 20.
- 12. (Original) The flowable pharmaceutical composition of claim 11, wherein said biocompatible oil has a dielectric constant below about 5.
- 13. (Previously Presented) The flowable pharmaceutical composition of claim 1, wherein said biocompatible oil, comprises at least about 33% by weight of said flowable pharmaceutical composition.
- 14. (Previously Presented) The flowable pharmaceutical composition of claim 13, wherein said biocompatible oil, comprises at least about 50% by weight of said flowable pharmaceutical composition.
- 15. (Previously Presented) The flowable pharmaceutical composition of claim 14, wherein said biocompatible oil, comprises at least about 75% by weight of said flowable pharmaceutical composition.
- 16. (Previously Presented) The flowable pharmaceutical composition of claim 14, wherein said biocompatible oil, comprises at least about 90% by weight of said flowable pharmaceutical composition.
- 17. (Previously Presented) The flowable pharmaceutical composition of claim 1, wherein said biocompatible oil, comprises at least about 50% by weight of said flowable pharmaceutical composition other than all pharmaceutically acceptable salts of analgesic agents in said pharmaceutical composition.
- 18. (Previously Presented) The flowable pharmaceutical composition of claim 17, wherein said biocompatible oil, comprises at least about 95% by weight of said flowable pharmaceutical composition other than all pharmaceutically acceptable salts of caine analgesic agents in said pharmaceutical composition.

19-21. (Canceled)

B3176942.1 - 3 -

- 22. (Previously Presented) The flowable pharmaceutical composition of claim 1, wherein said salt of said caine analysesic agent comprises at least about 4% and no more than about 67% by weight of said flowable pharmaceutical composition.
- 23. (Previously Presented) The flowable pharmaceutical composition of claim 22, wherein said biocompatible oil comprises at least about 70% by weight of said flowable pharmaceutical composition.
- 24. (Previously Presented) The flowable pharmaceutical composition of claim 22, wherein said salt of said caine analysesic agent comprises at least about 10% by weight of said flowable pharmaceutical composition.
- 25. (Previously Presented) The flowable pharmaceutical composition of claim 24, wherein said salt of said caine analysis agent comprises at least about 40% by weight of said flowable pharmaceutical composition.

26-29. (Canceled)

- 30. (Previously Presented) The flowable pharmaceutical composition of claim 1, wherein said salt of said caine analysesic agent is a pharmaceutically acceptable salt of lidocaine.
- 31. (Previously Presented) The flowable pharmaceutical composition of claim 30, wherein said salt of said caine analysis agent is lidocaine HCl.
- 32. (Original) The flowable pharmaceutical composition of claim 31, wherein said biocompatible oil is a vegetable oil.
- 33. (Original) The flowable pharmaceutical composition of claim 31, wherein said biocompatible oil is sesame oil.
- 34. (Previously Presented) A kit for treating a disease or condition of a subject, comprising (a) any of the flowable pharmaceutical compositions claimed above, and (b) instructions for administering said flowable pharmaceutical composition to a subject.

B3176942.1 - 4 -

- 35. (Previously Presented) A kit for treating pain of a subject, comprising (a) any of the flowable pharmaceutical compositions claimed above, and (b) instructions for administering said flowable pharmaceutical composition to a subject.
- 36. (Previously Presented) A kit for treating tinnutis of a subject, comprising (a) any of the flowable pharmaceutical compositions claimed above, and (b) instructions for administering said flowable pharmaceutical composition to a subject.
- 37. (Original) The kit of claim 34 wherein said instructions further provide for parenteral administration of said flowable pharmaceutical composition.
- 38. (Original) The kit of claim 34, wherein said instructions further provide for administration by injection of said flowable pharmaceutical composition.
- 39. (Currently Amended) A biocompatible pharmaceutical composition, consisting essentially of eomprising a biocompatible oil, at least about 2% by weight of a pharmaceutically acceptable inorganic salt of an analgesic agent, and no more than 10% by weight of a solvent in which said pharmaceutically acceptable inorganic salt of said analgesic agent is at least slightly soluble.
- 40. (Original) The pharmaceutical composition of claim 39, wherein said solvent comprises no more than 5% by weight of said pharmaceutical composition.
- 41. (Previously Presented) A biocompatible pharmaceutical composition, consisting essentially of one or more biocompatible oils and at least about 1% by weight of a pharmaceutically acceptable inorganic salt of a caine analgesic agent.

42-56. (Canceled)

57. (New) A flowable pharmaceutical composition comprising: a biocompatible oil and a therapeutically effective amount of a pharmaceutically acceptable inorganic salt of a caine analgesic agent, wherein said salt of said caine analgesic agent is at most sparingly soluble in said pharmaceutical composition, wherein said salt of said caine analgesic agent comprises at least about 3% and no more than about 80% by weight of said flowable pharmaceutical

B3176942.1 , - 5 -

composition, and said salt of said caine analgesic agent is a particle having a size about less than $150\ \mu m$.

B3176942.1 - 6 -